Get the Stockscreener App
22.34
1.87%
0.41
After Hours:
22.89
0.55
+2.46%
Catalyst Pharmaceuticals Inc stock is traded at $22.34, with a volume of 1.31M.
It is up +1.87% in the last 24 hours and up +4.10% over the past month.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
See More
Previous Close:
$21.93
Open:
$22
24h Volume:
1.31M
Relative Volume:
1.44
Market Cap:
$2.62B
Revenue:
$434.48M
Net Income/Loss:
$68.15M
P/E Ratio:
22.12
EPS:
1.01
Net Cash Flow:
$114.96M
1W Performance:
+5.63%
1M Performance:
+4.10%
6M Performance:
+40.77%
1Y Performance:
+58.44%
1-Day Range:
$21.63
$23.02
1-Week Range:
$20.87
$23.02
52-Week Range:
$13.00
$24.27
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Name
Catalyst Pharmaceuticals Inc
Sector
Industry
Phone
(305) 529-2522
Address
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
22.34 | 2.62B | 434.48M | 68.15M | 114.96M | 1.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Initiated | Stephens | Overweight |
| Mar-14-24 | Initiated | Citigroup | Buy |
| Mar-07-24 | Initiated | BofA Securities | Buy |
| Dec-21-23 | Initiated | Oppenheimer | Outperform |
| Aug-24-22 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-07-18 | Resumed | Piper Jaffray | Overweight |
| Oct-05-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-26-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Sep-30-14 | Reiterated | ROTH Capital | Buy |
| Sep-16-14 | Reiterated | ROTH Capital | Buy |
| Sep-15-14 | Reiterated | H.C. Wainwright | Buy |
| Oct-21-13 | Reiterated | Aegis Capital | Buy |
| Sep-24-13 | Initiated | Maxim Group | Buy |
| Sep-06-13 | Reiterated | Aegis Capital | Buy |
| Apr-18-13 | Initiated | Aegis Capital | Buy |
| Aug-27-12 | Upgrade | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| Oct-01-09 | Upgrade | Merriman | Sell → Neutral |
| May-29-09 | Downgrade | Hapoalim | Neutral → Underperform |
| May-29-09 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| Dec-15-08 | Initiated | Merriman Curhan Ford | Buy |
| Nov-28-07 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jan-31-07 | Initiated | Stifel Nicolaus | Buy |
| Jan-05-07 | Initiated | First Albany | Buy |
View All
Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock - Yahoo Finance
Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals Recognized as One of North - GlobeNewswire
Segall Bryant & Hamill LLC Makes New Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals chief medical officer sells $805,562 in stock - Investing.com India
Catalyst Pharmaceuticals chief medical officer sells $805,562 in stock By Investing.com - Investing.com South Africa
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Catalyst Pharmaceuticals chairman sells $3.6 million in stock By Investing.com - Investing.com South Africa
Catalyst Pharmaceuticals Insider Trades Send A Signal - Benzinga
Pacer Advisors Inc. Cuts Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Quest Partners LLC Grows Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals chairman sells $3.6 million in stock - Investing.com
Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals, Inc. (CPRX) Hit a 52 Week High, Can the Run Continue? - MSN
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
Catalyst Pharmaceuticals CEO to Present at Major Healthcare Conferences | CPRX Stock News - StockTitan
GSA Capital Partners LLP Invests $625,000 in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Coverage Initiated at Stephens - MarketBeat
Principal Financial Group Inc. Sells 63,273 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Stephens & Co. Initiates Coverage of Catalyst Pharmaceuticals (CPRX) with Overweight Recommendation - MSN
Catalyst Pharmaceuticals chairman sells shares worth $3.1 million - Investing.com
Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock - Yahoo Finance
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Royce & Associates LP - MarketBeat
Catalyst Pharmaceuticals Board Member Trades $11.51M In Company Stock - Benzinga
Catalyst Pharmaceuticals chairman sells $11.5 million in stock - Investing.com
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work - The Manila Times
Catalyst Pharmaceuticals Named Among BioSpace's Top 50 Best Places to Work 2025 | CPRX Stock News - StockTitan
We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Profit Is Only A Baseline For What They Can Achieve - Simply Wall St
Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings May Just Be The Starting Point - Yahoo Finance
Los Angeles Capital Management LLC Buys 123,020 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Brokerages Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Price Target at $30.50 - MarketBeat
CWA Asset Management Group LLC Makes New Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Price Target Raised to $36.00 at Truist Financial - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Purchased by Meritage Portfolio Management - MarketBeat
Catalyst Pharmaceuticals Inc (CPRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Catalyst Pharmaceuticals Inc (CPRX) Q3 2024 Earnings Call Highli - GuruFocus.com
Catalyst Pharmaceuticals Inc (CPRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Catalyst Pharmaceuticals' (CPRX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q3 2024 Earnings Call Transcript - Insider Monkey
With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Makes An Interesting Case - Yahoo Finance
Catalyst Pharmaceuticals Reports Strong Q3 2024 Earnings - TipRanks
Earnings call: Catalyst Pharma reports robust Q3 results, raises guidance - Investing.com
Catalyst Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2024 - Marketscreener.com
Earnings call: Catalyst Pharma reports robust Q3 results, raises guidance By Investing.com - Investing.com Canada
Market Participants Recognise Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Earnings - Simply Wall St
CPRX Q3 Earnings & Revenues Beat Estimates, '24 View Raised, Stock Up - Nasdaq
Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings and Revenue Estimates - Yahoo Finance
Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Catalyst Pharmaceuticals Inc Stock (CPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):